Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002902 · ClinicalTrials.gov registry record · Phase 1
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002902 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine.
The verdict
NCT00002902, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.
Interventions
- DRUG irinotecan hydrochloride
- DRUG raltitrexed
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002902
The ClinicalTrials.gov registry entry for NCT00002902 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00002902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002902 about?
NCT00002902 is a clinical study titled "Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tum...
What is the current status of trial NCT00002902?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-04.
What interventions are being tested in trial NCT00002902?
The interventions under investigation include: irinotecan hydrochloride (DRUG), raltitrexed (DRUG).
Who is sponsoring clinical trial NCT00002902?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.